CA-BELKIN
25.6.2024 17:01:34 CEST | Business Wire | Press release
Belkin, a leading consumer electronics brand for 40 years, today announced the availability of the BoostCharge Pro Magnetic Power Bank, built with Qi2 wireless charging technology. It is available to order today in 5K and 10K options, and in five fresh new colors – cyber lime, sand, pink, blue, and gold.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625730951/en/
Belkin BoostCharge Pro Magnetic Power Bank 5K in cyber lime, sand, pink, blue and gold color options. (Photo: Business Wire)
Unveiled earlier this year, Belkin’s Qi2 power bank lineup delivers up to 15W of fast charging power for iPhone 12 models and later, without the hassle of cables. They are engineered with an integrated kickstand for propping the phone up while streaming, reading or chatting, and work with magnetic and MagSafe cases up to 3mm thick. They are designed to fit perfectly on the back of iPhone without obstructing camera. “Power pass-through” allows for charging the power bank and attached devices in one simple action via USB-C port.
BoostCharge Pro Magnetic Power Bank 5K
- Fast charges iPhone 12 models and later up to 15W with Qi2 when battery pack is plugged in, and up to 7.5W when used as battery pack
- Provides up to 16 hours of additional battery life1
- Built with 1 x USB-C port to charge two devices simultaneously2
- Packaged with USB-C to USB-C cable to start charging right out of the box
- Available in black, cyber lime, sand, pink, and blue color options; gold available in European markets only
- $59.95 USD
BoostCharge Pro Magnetic Power Bank 10K
- Fast charges iPhone 12 models and later up to 15W with Qi2 (delivers 0-25% charge in 21 minutes3), or up to 20W with integrated USB-C cable
- Provides up to 35 hours of additional battery life4
- Built with 1 x USB-C port and integrated USB-C cable to charge three devices simultaneously5
- Available in black
- $99.95 USD
In line with Belkin’s commitment to build products more responsibly, the BoostCharge Pro Magnetic Power Bank offerings are made with a minimum of 72% post-consumer recycled materials (PCR) and packaged in 100% plastic-free packaging.
Media kit can be found HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
___________
1 Maximum additional video playback hours calculated by comparing the mAh capacity of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on differing factors for individual users.
2 When one device is charging: 7.5W wireless or USB-C 12W max output. When two devices are charging: 5W wireless + 5W max USB-C
3 Based on internal tests using iPhone 15; results may vary depending on various conditions.
4 Contains a 10,000 mAh internal battery. Amount of discharge to user’s device is less and may vary depending on various conditions. Maximum additional video playback hours calculated by comparing the capacity of the internal battery of this power bank with the maximum video playback hours achievable by the iPhone 15 under normal conditions. Actual results will vary depending on conditions and use.
5 When one device is charging: 15W wireless, or USB-C 20W max output. When two devices charging: 7.5W wireless + 10W max USB-C. When three devices charging: 15W max shared
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625730951/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom